The Latest
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Immune drug developer Odyssey Therapeutics is gearing up for its second chance at an IPO, outlining terms for an offering that could raise $211 million or more.
Updated 18Â hours ago -
Permission granted by Nasdaq, Inc. / Vanja Savic
Deep Dive // Emerging biotechBiotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.
-
Getty Images
With $97M, Latus pursues a different kind of Huntington’s gene therapy
The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.
-
Getty Images
Celcuity strengthens case for ASCO-spotlighted breast cancer drug
The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.
-
Michael Santiago/Getty Images via Getty Images
IPO windowTwo biotechs raise a combined $556M in latest spurt of IPOs
Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a stretch of large IPOs this year that collectively raised almost $3.2 billion.
-
Douglas Olivares via Getty Images
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.
-
Getty Images
News roundupBristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.
-
Getty Images
News roundupSummit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.
-
Courtesy of UniQure
UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy
News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an uncertain future in the U.S.
-
Maddie Meyer via Getty Images
VaccinesModerna sees revenue bump from international COVID vaccine sales
The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s vaulted its stock price in 2026.
-
Getty Images
Merck still sees ‘compelling’ outlook for Terns leukemia drug
Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
UCB’s buyout of Candid is the sector’s seventh acquisition in the last week, adding to a pace that’s turning 2026 into one of the most active years ever for biotech M&A.
Updated May 4, 2026 -
Courtesy of Eli Lilly
Obesity drugsLilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
A strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for both profit and revenue.
-
Michael M. Santiago via Getty Images
IPO windowAvalyn, in pursuit of better lung drugs, banks $300M in an IPO
The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.
-
Elizabeth Regan/BioPharma Dive
Chiesi to buy KalVista in $1.9B deal for rare disease drug
The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.
-
Courtesy of Teva Pharmaceutical
Brain drug revivalTeva nabs experimental Tourette drug in $700M Emalex buyout
A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
BeOne Medicines grabbed an option to acquire an antibody from HuaHui Health that acts on three known cancer targets: PD-1, CTLA-4 and VEGF.
Updated May 1, 2026 -
Getty Images
News roundup
FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multiple myeloma drug.
-
Getty Images
Pfizer deals extend patent life for a top-selling rare disease drug
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
-
Courtesy of Boehringer Ingelheim
Obesity drugsBoehringer dual-acting obesity shot hits mark in Phase 3 trial
Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.
-
Getty Images
Emerging biotechCoultreon banks $125M to support testing of former Galapagos immune drug
Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases.
-
Getty Images
News roundup
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.
-
Getty Images
Veradermics soars on positive data for baldness treatment
The results could support the first approval in decades for an oral medicine that can treat male pattern baldness, though the therapy will face competition from generics and over-the-counter medications.
-
Permission granted by Intellia Therapeutics
Gene editingIntellia CRISPR drug succeeds in late-stage study against rare swelling disorder
The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.
-
Permission granted by Ajax Therapeutics
Lilly to buy startup Ajax in bid for a better JAK drug
Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.
